Literature DB >> 8111706

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.

M Nagayama1, A Sato, H Hayakawa, T Urano, Y Takada, A Takada.   

Abstract

BACKGROUND: Evidence suggests that plasminogen activators and their inhibitors play an important role in tumor spread.
METHODS: In this study, we measured the antigen levels of urokinase (u-PA), tissue plasminogen activator (t-PA), type 1 plasminogen activator inhibitor (PAI-1), and type 2 plasminogen activator inhibitor (PAI-2), and cancer tissue (19 adenocarcinomas and 19 squamous cell carcinomas) and normal lung tissue.
RESULTS: u-PA, PAI-1, and PAI-2 antigen levels in cancer tissue were significantly higher than those in normal tissue (P < 0.001 in u-PA and PAI-1; P < 0.005 in PAI-2), whereas t-PA antigen levels in cancer tissue were significantly lower than those in normal tissue (P < 0.005). In case with lymph node involvement (LN+ cases), PAI-2 antigen levels were significantly lower than those in cases without lymph node involvement (LN- cases) (P < 0.02), whereas there was no difference in either u-PA or PAI-1 antigen levels between these two groups. Furthermore, u-PA antigen levels showed a significant positive correlation with PAI-2 antigen levels in LN- cases (r = 0.696; P < 0.005), although there was no correlation between these two parameters in LN+ cases.
CONCLUSIONS: The antigen levels of u-PA, PAI-1, and PAI-2 in cancer tissue were significantly higher than those in normal tissue, and lower content of PAI-2 was associated with lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8111706     DOI: 10.1002/1097-0142(19940301)73:5<1398::aid-cncr2820730514>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

Review 1.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer.

Authors:  G Cox; W P Steward; K J O'Byrne
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 3.  Impact of smoking status on the biological behavior of lung cancer.

Authors:  Ichiro Yoshino; Yoshihiko Maehara
Journal:  Surg Today       Date:  2007-08-27       Impact factor: 2.549

4.  High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.

Authors:  Ross Smith; AiQun Xue; Anthony Gill; Christopher Scarlett; Alexander Saxby; Adele Clarkson; Thomas Hugh
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

5.  Regulation of activator protein-1 activity in the mediastinal lymph node metastasis of lung cancer.

Authors:  K Ichiki; N Mitani; Y Doki; H Hara; T Misaki; I Saiki
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma.

Authors:  M Sunagawa; G W Huang; M Nakamura; T Kosugi
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

7.  Polymorphic nucleic Acid binding of bioactive isoquinoline alkaloids and their role in cancer.

Authors:  Motilal Maiti; Gopinatha Suresh Kumar
Journal:  J Nucleic Acids       Date:  2009-12-15

8.  Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas.

Authors:  I Bolon; V Gouyer; M Devouassoux; B Vandenbunder; N Wernert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1995-11       Impact factor: 4.307

9.  Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas.

Authors:  M Olivero; M Rizzo; R Madeddu; C Casadio; S Pennacchietti; M R Nicotra; M Prat; G Maggi; N Arena; P G Natali; P M Comoglio; M F Di Renzo
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

10.  Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.

Authors:  H Yoshino; Y Endo; Y Watanabe; T Sasaki
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.